Siren Acquires Nearly 2.5 Million Shares of Erasca
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Source: Fool
- Share Acquisition: Siren disclosed in its May 14, 2026 SEC filing that it acquired 2,486,997 shares of Erasca (ERAS) for an estimated $29.39 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: Following this acquisition, Siren's stake in Erasca now stands at 5.04%, with the quarter-end value of Erasca increasing by $149.35 million due to both the new shares and underlying price appreciation, reflecting market recognition of its potential.
- Outstanding Stock Performance: As of May 13, 2026, Erasca's stock price reached $10.46, marking a 700% increase over the past year, significantly outperforming the S&P 500's 26% rise, showcasing its robust performance in the biotech sector.
- Strong Funding and Growth Potential: Erasca ended the first quarter with approximately $409 million in cash and marketable securities, which is expected to fund aggressive development plans into the second half of 2028, particularly in the treatment of RAS-driven cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 13.980
Low
2.00
Averages
5.50
High
11.00
Current: 13.980
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a market capitalization loss exceeding $2.8 billion, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 to RevMed's RMC-6236, which could expose the company to intellectual property disputes, further impacting its position in the highly competitive cancer treatment market.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, underscoring potential safety issues that could threaten the company's future growth prospects.
See More
Multiple Companies Facing Class Action Lawsuits
- BitGo Lawsuit Overview: BitGo Holdings, Inc. (NYSE:BTGO) faces a class action lawsuit for the period from January 22, 2026, to May 13, 2026, due to failure to disclose the impact of declining digital asset prices on its financial performance, with a lead plaintiff deadline of August 7, 2026.
- Erasca Lawsuit Details: Erasca, Inc. (NASDAQ:ERAS) is involved in a class action lawsuit for the period from January 14, 2025, to April 26, 2026, alleging improper comparisons in preclinical data that risked patent protections, with a lead plaintiff deadline of August 10, 2026.
- Nano-X Lawsuit Issues: Nano-X Imaging Ltd. (NASDAQ:NNOX) faces a class action lawsuit for the period from March 31, 2025, to April 17, 2026, due to overstated operational efficiency and product demand, leading to increased operating expenses and cash burn, with a lead plaintiff deadline of August 11, 2026.
- Microsoft Lawsuit Background: Microsoft Corporation (NASDAQ:MSFT) is involved in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, for failing to disclose multiple issues with its Copilot product line, resulting in a decline in market share, with a lead plaintiff deadline of August 11, 2026.
See More
Erasca Faces Securities Class Action Over Patient Death and Misleading Data
- Stock Price Collapse: Following the disclosure of a patient death during the ERAS-0015 clinical trial on April 27, 2026, Erasca's stock plummeted by 53.9%, resulting in a loss of $11.59 per share, highlighting severe investor concerns regarding the company's transparency.
- Concealed Safety Signals: The lawsuit alleges that Erasca's management failed to timely disclose the patient death, leading to investor misconceptions about the safety of ERAS-0015, which adversely affected investor decisions and confidence.
- Data Comparison Controversy: Erasca previously claimed that ERAS-0015 achieved comparable antitumor activity to Revolution Medicines' RMC-6236, but later admitted that these comparisons were not based on direct clinical trials, further intensifying doubts about the validity of its data.
- Legal Implications: The court has set August 10, 2026, as the deadline for applying for lead plaintiff status, urging investors to quickly gather relevant evidence to participate in the lawsuit, with potential for significant compensation at stake.
See More
Erasca Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, to apply as lead plaintiffs.
- Allegations of Misrepresentation: The lawsuit alleges that Erasca and its executives failed to disclose material adverse facts regarding ERAS-0015's preclinical data, which could violate patent and trade secret protections, resulting in significant losses for investors.
- Stock Price Plummet: Following the April 28, 2026 disclosure that ERAS-0015 may infringe on Revolution Medicines' patent, Erasca's stock price fell by 48%, from $19.15 to $9.90, severely impacting investor confidence and market perception.
- Legal Consultation Opportunity: Bragar Eagel & Squire encourages affected investors to reach out for legal advice, highlighting the potential implications of this lawsuit on investor rights and the importance of legal support in such matters.
See More
Erasca Investors Alert: Lawsuit Deadline Approaches
- Lawsuit Reminder: The Law Offices of Howard G. Smith remind investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to file a lead plaintiff motion by August 10, 2026, to participate in the ongoing securities fraud lawsuit against the company.
- Stock Price Drop: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, to close at $19.15 per share after receiving a patent infringement allegation from Revolution Medicines, Inc., resulting in significant losses for investors.
- Clinical Data Disclosure: On the same day, Erasca reported preliminary Phase 1 clinical data for ERAS-0015, revealing a patient death approximately one month after treatment initiation, causing the stock price to plummet by $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, further exacerbating investor losses.
- False Statements Allegation: The lawsuit alleges that throughout the Class Period, Erasca failed to disclose critical adverse facts regarding ERAS-0015, particularly that its preclinical data was improperly compared to Revolution Medicines, misleading investors about the company's business prospects.
See More
Erasca Faces Class Action Lawsuit Over Patent Violations
- Stock Price Plunge: Erasca's stock price plummeted approximately 53.9%, losing $11.59 per share from $21.49 to $9.90 after the revelation of improper preclinical data, indicating a severe crisis in market trust and significant losses for investors.
- Lawsuit Allegations: The class action lawsuit alleges that Erasca engaged in improper comparisons with Revolution Medicines' RMC-6236, potentially leading to patent infringement and trade secret misappropriation, with management failing to disclose these risks to investors, exacerbating investor concerns.
- Financing Motivation: The lawsuit claims that Erasca's $258.8 million stock offering on January 23, 2026, was aimed at maintaining an artificially inflated stock price, coinciding with management's repeated controversial comparisons at the J.P. Morgan Healthcare Conference, suggesting awareness of the vulnerability of these claims.
- Investor Rights: Investors are informed that those who purchased Erasca shares between January 14, 2025, and April 26, 2026, and suffered losses may be eligible to join the lawsuit, highlighting the critical importance of preclinical data disclosure obligations in the oncology sector.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a market capitalization loss exceeding $2.8 billion, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 to RevMed's RMC-6236, which could expose the company to intellectual property disputes, further impacting its position in the highly competitive cancer treatment market.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, underscoring potential safety issues that could threaten the company's future growth prospects.
See More
Multiple Companies Facing Class Action Lawsuits
- BitGo Lawsuit Overview: BitGo Holdings, Inc. (NYSE:BTGO) faces a class action lawsuit for the period from January 22, 2026, to May 13, 2026, due to failure to disclose the impact of declining digital asset prices on its financial performance, with a lead plaintiff deadline of August 7, 2026.
- Erasca Lawsuit Details: Erasca, Inc. (NASDAQ:ERAS) is involved in a class action lawsuit for the period from January 14, 2025, to April 26, 2026, alleging improper comparisons in preclinical data that risked patent protections, with a lead plaintiff deadline of August 10, 2026.
- Nano-X Lawsuit Issues: Nano-X Imaging Ltd. (NASDAQ:NNOX) faces a class action lawsuit for the period from March 31, 2025, to April 17, 2026, due to overstated operational efficiency and product demand, leading to increased operating expenses and cash burn, with a lead plaintiff deadline of August 11, 2026.
- Microsoft Lawsuit Background: Microsoft Corporation (NASDAQ:MSFT) is involved in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, for failing to disclose multiple issues with its Copilot product line, resulting in a decline in market share, with a lead plaintiff deadline of August 11, 2026.
See More
Erasca Faces Securities Class Action Over Patient Death and Misleading Data
- Stock Price Collapse: Following the disclosure of a patient death during the ERAS-0015 clinical trial on April 27, 2026, Erasca's stock plummeted by 53.9%, resulting in a loss of $11.59 per share, highlighting severe investor concerns regarding the company's transparency.
- Concealed Safety Signals: The lawsuit alleges that Erasca's management failed to timely disclose the patient death, leading to investor misconceptions about the safety of ERAS-0015, which adversely affected investor decisions and confidence.
- Data Comparison Controversy: Erasca previously claimed that ERAS-0015 achieved comparable antitumor activity to Revolution Medicines' RMC-6236, but later admitted that these comparisons were not based on direct clinical trials, further intensifying doubts about the validity of its data.
- Legal Implications: The court has set August 10, 2026, as the deadline for applying for lead plaintiff status, urging investors to quickly gather relevant evidence to participate in the lawsuit, with potential for significant compensation at stake.
See More
Erasca Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, to apply as lead plaintiffs.
- Allegations of Misrepresentation: The lawsuit alleges that Erasca and its executives failed to disclose material adverse facts regarding ERAS-0015's preclinical data, which could violate patent and trade secret protections, resulting in significant losses for investors.
- Stock Price Plummet: Following the April 28, 2026 disclosure that ERAS-0015 may infringe on Revolution Medicines' patent, Erasca's stock price fell by 48%, from $19.15 to $9.90, severely impacting investor confidence and market perception.
- Legal Consultation Opportunity: Bragar Eagel & Squire encourages affected investors to reach out for legal advice, highlighting the potential implications of this lawsuit on investor rights and the importance of legal support in such matters.
See More
Erasca Investors Alert: Lawsuit Deadline Approaches
- Lawsuit Reminder: The Law Offices of Howard G. Smith remind investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to file a lead plaintiff motion by August 10, 2026, to participate in the ongoing securities fraud lawsuit against the company.
- Stock Price Drop: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, to close at $19.15 per share after receiving a patent infringement allegation from Revolution Medicines, Inc., resulting in significant losses for investors.
- Clinical Data Disclosure: On the same day, Erasca reported preliminary Phase 1 clinical data for ERAS-0015, revealing a patient death approximately one month after treatment initiation, causing the stock price to plummet by $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, further exacerbating investor losses.
- False Statements Allegation: The lawsuit alleges that throughout the Class Period, Erasca failed to disclose critical adverse facts regarding ERAS-0015, particularly that its preclinical data was improperly compared to Revolution Medicines, misleading investors about the company's business prospects.
See More
Erasca Faces Class Action Lawsuit Over Patent Violations
- Stock Price Plunge: Erasca's stock price plummeted approximately 53.9%, losing $11.59 per share from $21.49 to $9.90 after the revelation of improper preclinical data, indicating a severe crisis in market trust and significant losses for investors.
- Lawsuit Allegations: The class action lawsuit alleges that Erasca engaged in improper comparisons with Revolution Medicines' RMC-6236, potentially leading to patent infringement and trade secret misappropriation, with management failing to disclose these risks to investors, exacerbating investor concerns.
- Financing Motivation: The lawsuit claims that Erasca's $258.8 million stock offering on January 23, 2026, was aimed at maintaining an artificially inflated stock price, coinciding with management's repeated controversial comparisons at the J.P. Morgan Healthcare Conference, suggesting awareness of the vulnerability of these claims.
- Investor Rights: Investors are informed that those who purchased Erasca shares between January 14, 2025, and April 26, 2026, and suffered losses may be eligible to join the lawsuit, highlighting the critical importance of preclinical data disclosure obligations in the oncology sector.
See More
